Platelets最新文献

{"title":"<i>In vitro</i> investigations of the clot formation and resolution properties of cryopreserved platelets.","authors":"Lacey Johnson, Christopher Roan, Pearl Lei, Ben Winskel-Wood, Janhavi Mahajan, Denese C Marks","doi":"10.1080/09537104.2025.2607714","DOIUrl":"10.1080/09537104.2025.2607714","url":null,"abstract":"<p><p>While platelets for transfusion are traditionally stored at room temperature (20-24°C), cryopreservation at -80°C is attractive, as it facilitates an extension of the shelf-life from 7 days to several years. Cryopreserved platelets display enhanced procoagulant capacity, which may distort the balance between clot formation and resolution. Platelets were frozen at -80°C using DMSO and thawed and resuspended in fresh plasma before testing. Fresh components (day 1) were tested in parallel. The supernatant of thawed platelets contained a higher concentration of fibrinogen, plasminogen, TAFI, FXIII, PAI-1, and tPA, compared to fresh platelets. However, this was primarily due to the addition of fresh plasma at the time of platelet thawing, with the exception of PAI-1. Thawed platelets displayed a higher surface abundance of PAI-1 and FXIII, compared to fresh platelets. The clots formed by thawed platelets underwent retraction; although this was affected by time and platelet concentration. tPA-induced fibrinolysis, measured by thromboelastography (TEG), was not statistically different between fresh and thawed platelets. Although differences in the abundance of fibrinolytic mediators were observed in thawed platelets, compared to room temperature platelets, clot resolution properties were conserved. This work provides a more complete understanding of the overall hemostatic capacity of cryopreserved platelets.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2607714"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145971073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adaptive immune and platelet activation during the maintenance phase of therapy in adults with B cell acute lymphoblastic leukemia.","authors":"Zekhethelo A Mkhwanazi, Tawanda M Nyambuya, Edwig Shingenge, Bongani B Nkambule","doi":"10.1080/09537104.2026.2636463","DOIUrl":"10.1080/09537104.2026.2636463","url":null,"abstract":"<p><strong>Background: </strong>Maintenance therapy is an integral component of treatment for B cell acute lymphoblastic leukemia (B-ALL) and has demonstrated clinical efficacy. However, features of immune activation and an increased thrombotic risk may persist beyond the induction phase of treatment. The mechanisms underlying immune activation during the maintenance phase of B-ALL remain unclear. Therefore, this study aimed to evaluate immune activation and thrombotic risk in adult patients with B-ALL undergoing maintenance therapy.</p><p><strong>Method: </strong>This prospective study was conducted at Windhoek Central Hospital and Katutura State Hospital in Namibia. Adult patients with B-ALL receiving maintenance therapy (<i>n</i> = 16) and eighteen controls (<i>n</i> = 18) were enrolled. Plasma concentrations of D-dimer, thrombin, and platelet factor 4 (PF-4) were quantified using enzyme-linked immunosorbent assay and the surface expression of immune checkpoint and activation markers on CD4⁺ T cells, B lymphocytes, and platelets were measured using flow cytometry.</p><p><strong>Results: </strong>Patients with B-ALL demonstrated elevated thrombin (<i>p</i> = .01) and PF4 (<i>p</i> = .02) concentrations compared with healthy controls. In addition, the expression of the activation marker CD69 (<i>p</i> < .001), and immune checkpoints PD-L1 (<i>p</i> < .001) and CTLA-4 (<i>p</i> < .001) were increased on the surface of CD4⁺ T cells. While PD-1 expression remained comparable between the groups (<i>p</i> = .90). On B lymphocytes, CD69 expression levels were similar between groups (<i>p</i> = .11). Whereas the levels of PD-L1 (<i>p</i> < .001) and CTLA-4 (<i>p</i> = .02) were elevated. Notably, PD-1 expression was reduced in patients with B-ALL (<i>p</i> = .02). The expression of CD62P was increased in patients with B-ALL when compared with controls (<i>p</i> < .001).</p><p><strong>Conclusion: </strong>Adult patients with B-ALL undergoing maintenance therapy exhibits increased lymphocyte and platelet activation, which may be associated with an elevated thrombotic risk despite normal D-dimer levels.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2636463"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147378343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemiluminescence resonance energy transfer-based method to investigate the platelet surface molecule in acute myocardial infarction.","authors":"Linyan He, Bing Ding, Fei Shen, Liqian Xie, Yunxiao Zhao, Xia Wang, Yiming Zhao","doi":"10.1080/09537104.2026.2675248","DOIUrl":"10.1080/09537104.2026.2675248","url":null,"abstract":"<p><p>The chemiluminescence resonance energy transfer (CRET)-based method was applied to the detect of CD61 and CD62P (P-selectin) on the surface of platelet in patients with acute myocardial infarction (AMI) and healthy controls. Patients admitted to the Department of Emergency in The First Affiliated Hospital of Soochow University from May 2025 to December 2025 were recruited. We studied 22 AMI patients who were matched with 22 controls. The coefficient of variations and standard curves of indexes were calculated. Expressions of CD61 and CD62P in plasma were evaluated by CRET assay. Standard curve property for CD61 and CD62P: R² .995 and 0.9999. The coefficient of variation in CRET system was 3.39%, 1.76% (QC high), 6.25% and 7.16% (QC low) for CD61 and CD62P, respectively. CRET data showed the agonist (arachidonic acid and ADP) concentration dependency on platelet activation. AMI patients had higher basal CD62P levels when compared to controls. The platelet aggregation rate of AMI patients had a strong positive correlation with the expression of CD62P (<i>r</i> = 0.8354, <i>p</i> < .0001). In the healthy controls, the platelet CD61 and CD62P expression detected by flow cytometry showed a positive correlation with that evaluated by CRET (<i>r</i> = 0.4296, <i>p</i> = .0460; <i>r</i> = 0.5662, <i>p</i> = .0060, respectively). After platelet activation with AA or ADP, the expression levels of CD62P detected by flow cytometry were positively correlated with those measured by the CRET method (<i>r</i> = 0.6195, <i>p</i> = .0021; <i>r</i> = 0.7663, <i>p</i> < .0001, respectively). Expressions of CD62P elevated after agonist stimulation in AMI patients and controls in vitro. With the biomarker of CD62P as the model, the Area Under Curve (AUC) was 0.9236 (<i>p</i> < .0001). The cutoff value of CD62P to evaluate platelet reactivity by CRET was 3.985%. This one-step CERT assay provided a new approach to detect platelet activity of acute myocardial infarction.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2675248"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147964245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of bleeding and thromboembolic complications in patients on chronic hemodialysis with the total thrombus-formation analysis system.","authors":"Zorica M Dimitrijevic, Svetlana Apostolovic, Danijela D Tasic, Tatjana P Cvetkovic, Milan V Lazarevic, Kazuya Hozokawa, Anna Ågren, Håkan Wallén","doi":"10.1080/09537104.2026.2614709","DOIUrl":"10.1080/09537104.2026.2614709","url":null,"abstract":"<p><p>Patients receiving hemodialysis (HD) are susceptible to bleeding and thrombosis. We assessed whether the T-TAS assay - which measures platelet thrombus formation (PL-AUC) and fibrin-rich thrombus formation (AR-OT) in whole blood under flow - could predict these complications in 176 chronic HD patients, monitoring bleeding and thromboembolic events over one year. During follow-up, 29 patients (16.5%) experienced at least one major or clinically relevant non-major bleeding (CRNMB) event, while 31 patients (17.6%) had at least one thromboembolic event. Patients with low thrombogenicity (PL-AUC below the median) had a more than fivefold increased risk of major bleed/CRNMB in multivariate analyses, and a C-statistic (ROC-AUC; 95% CI) for discrimination between future bleeding/no bleeding of 0.82 (0.74-0.90). AR-OT data showed comparable results. Further, the risk of thromboembolism was significantly lower in patients with PL-AUC below the median (multivariate OddsRisk [OR] ~0.20; C-statistic for thromboembolism/no thromboembolism of 0.73 [0.64-0.83]). Reduced fibrin-rich thrombus formation (AR-OT above median) was associated with ORs below 0.50 to develop thromboembolism in multivariate analyses (C-statistic 0.75 [0.65-0.85]). Excluding patients on oral antithrombotic agents (i.e. aspirin (<i>n</i> = 20) and warfarin (<i>n</i> = 14)), resulted in similar findings. In conclusion, T-TAS is a promising tool for assessing bleeding and thrombosis risk in HD patients.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2614709"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146047089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Branched endovascular aortic aneurysm repair decreases platelet reactivity and platelet-rich thrombus formation - a prospective, cohort study.","authors":"Aleksandra Gąsecka, Ewelina Błażejowska, Agata Konieczka, Mateusz Leśniewski, Magdalena Ostaszewska, Michał Łomiak, Magdalena Gajewska, Sylwester Rogula, Łukasz Szarpak, Krzysztof J Filipiak, Mateusz Zawadka, Katarzyna Jama, Paweł Andruszkiewicz, Marcin Grabowski, Tomasz Jakimowicz","doi":"10.1080/09537104.2025.2458622","DOIUrl":"10.1080/09537104.2025.2458622","url":null,"abstract":"<p><p>Appropriate platelet function determines both the perioperative haemostasis and the risk of postoperative thrombotic complications in patients undergoing branched endovascular repair (bEVAR) of thoracoabdominal aortic aneurysm (TAAA). We aimed to assess the effect of bEVAR on platelet function and the predictive value of preoperative platelet function for postoperative bleeding. We measured platelet function using impedance aggregometry and total thrombus-formation analysis system in 50 consecutive patients, with TAAA undergoing elective bEVAR. After bEVAR, platelet reactivity was assessed using ASPI test, ADP test and TRAP test and thrombus size decreased, whereas time to clot formation increased, compared to baseline (<i>p</i> ≤ .042 for all). Preoperative platelet reactivity in the TRAP test was lower in patients who experienced post-operative bleeding, defined as ≥3 red blood cell units transfusion, compared to those who did not (<i>p</i> = .038). Baseline hemoglobin level <13 g/dl and TRAP test result ≤29.5 AUC increased the odds of bleeding by 5.4-fold and 6.8-fold, respectively, independent of other clinical variables. We conclude that in patients with TAAA undergoing bEVAR, platelet reactivity and platelet-rich thrombus formation decreased directly after the operation. Preoperative hemoglobin level and platelet reactivity in the TRAP test were independent predictors of postoperative bleeding complications.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"36 1","pages":"2458622"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of thromboxane generation with the bleeding events in aspirin users.","authors":"Yawen Liu, Yijie Liu, Feiqing Liang, Lu Lin, Zhipeng Xie, Jinxia Mai, Zhuoyi Wu, Min Huang, Shilong Zhong","doi":"10.1080/09537104.2025.2473953","DOIUrl":"10.1080/09537104.2025.2473953","url":null,"abstract":"<p><p>Coronary artery disease is among the leading causes of morbidity and mortality worldwide, posing a significant threat to human health and life. Aspirin is widely used in the treatment of coronary artery disease, however, long-term use may increase the risk of bleeding. Urinary 11-dehydro-TXB2, a biomarker indicative of platelet activation, has been associated with thrombotic events, but its association with bleeding events remains unexplored. This study aimed to assess the predictive value of TXB2-M levels for bleeding events in patients with coronary artery disease undergoing aspirin therapy. Multifactorial logistic regression analysis was employed to evaluate the potential of TXB2-M levels as a reliable marker for bleeding risk following aspirin use. Among patients with coronary artery disease treated with aspirin, those with lower TXB2-M levels exhibited an increased risk of bleeding events within three years (Hazard Ratio: 0.46; 95% Confidence Interval: 0.26-0.79; <i>P</i> < 0.05). Additionally, variations in TXB2-M levels were observed across different demographic groups. This study reinforces the validity of TXB2-M levels as a biomarker for identifying patients at elevated risk of bleeding, thus facilitating the implementation of personalized treatment strategies to minimize bleeding risks while preserving the efficacy of antithrombotic therapy.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"36 1","pages":"2473953"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multi-color flow cytometric method for characterizing murine reticulated platelets using SYTO 13.","authors":"Muataz Ali Hamad, Krystin Krauel, Nancy Schanze, Mark Zurek, Christoph B Olivier, Peter Kohl, Thomas G Nührenberg, Daniel Duerschmied","doi":"10.1080/09537104.2025.2489020","DOIUrl":"https://doi.org/10.1080/09537104.2025.2489020","url":null,"abstract":"<p><p>Reticulated platelets (RP) are immature platelets with heightened RNA content. An increased level of RP in the circulation is associated with various pathological conditions. In this study, we employed a novel flow cytometry approach for RP detection in mice, utilizing the nucleic acid dye SYTO 13 in conjunction with a platelet-specific marker (anti-mouse CD42b-DyLight 649). The efficacy of SYTO 13 for RP identification was confirmed by higher circulating RP levels in platelet-depleted mice during the recovery phase (35% ± 13%) compared to untreated mice (11% ± 1%, <i>n</i> = 9, <i>p</i> < .0001). We further characterized murine RP by exploring the surface expression of the platelet activation marker P-selectin. While there was no preactivation at baseline, stimulation with a thrombin receptor agonist (PAR-4) resulted in a higher increase in the percentage of P-selectin-positive platelets in RP (93% ± 6%) compared to non-RP (77% ± 14%, <i>n</i> = 6, <i>p</i> = .0065). In addition, RP exhibited higher geometric mean fluorescence intensity levels than non-RP (1874 ± 1278 <i>versus</i> 859 ± 549, <i>n</i> = 6, <i>p</i> = .02). Our proof-of-principle study demonstrates the efficacy of SYTO 13 in combination with platelet (activation) markers for identifying RP in both resting and activated states. This method holds promise for simultaneously monitoring RP levels and platelet activation in murine models of human disease.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"36 1","pages":"2489020"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case with a novel GATA1 variant mimicking immune thrombocytopenia attacks.","authors":"Elif Habibe Aktekin, Serdar Ceylaner, Şeyda Beşen, Ayşe Erbay, Nalan Yazıcı","doi":"10.1080/09537104.2025.2500499","DOIUrl":"10.1080/09537104.2025.2500499","url":null,"abstract":"<p><p>One of the leading thrombocytopenia occasions in childhood is immune thrombocytopenia (ITP). Small number of these patients do not respond to treatment methods known to be effective for ITP such as corticosteroids, intravenous immunoglobulin and thrombopoietin receptor agonists (eltrombopag, romiplostim, etc.) and have serious bleeding symptoms. We present a case in which a molecular genetic analysis was performed due to challenging responses to medical treatment for severe systemic bleeding symptoms which were similar to ITP. A hemizygous variant was detected in the <i>GATA1</i> gene and a homozygous variant in the <i>ATP2A1</i> gene for Brody myopathy. Eltrombopag, romiplostim, IVIG and corticosteroid were applied to resistant thrombocytopenia of the patient without knowing the cause. Patient had response in platelet counts in some occasions. This situation attracted our attention after the detection of this GATA variant in the etiopathogenesis of thrombocytopenia. Further investigations should be performed for much more rare causes of thrombocytopenia in patients with refractory thrombocytopenia attacks.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"36 1","pages":"2500499"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved micro-sampling methodology enables accurate platelet function analysis.","authors":"Tyler L Horn, Abhishek Sadhu, Hind O Alosaimi, Chris I Jones, Craig E Hughes","doi":"10.1080/09537104.2025.2588739","DOIUrl":"https://doi.org/10.1080/09537104.2025.2588739","url":null,"abstract":"<p><p>Micro-sampling for platelet function assays offers a minimally invasive alternative to venipuncture that may facilitate point-of-care testing. We have developed a new micro-sampling methodology for human and mouse and evaluated these methods for platelet function analysis. Blood was collected by venepuncture or our new finger-prick sampling method in humans, and by terminal bleeding or a modified tail vein bleeding method in mice. Platelet activation was assessed by flow cytometry, measuring fibrinogen binding and P-selectin exposure in response to ADP, CRP-XL or TRAP-6 in humans (<i>n</i> = 14) and fibrinogen binding in response to ADP, CRP-XL in mice (<i>n</i> = 5). In humans, platelet sensitivity (EC₅₀) and capacity (maximal minus minimal response) showed no significant differences between capillary and venous samples, except for a higher EC₅₀ of P-selectin exposure to CRP-XL in capillary samples (0.179 µg/mL), compared to venous samples (0.026 µg/mL). This may be clinically relevant but requires further investigation. In mice, no significant differences were observed in EC₅₀ or capacity in response to ADP or CRP-XL between the terminal bleeding techniques and our modified tail vein method. Our new finger-prick sampling and tail vein bleeding methods are viable alternatives to the standard methods used for platelet function analysis. They maintain assay accuracy while improving accessibility and reducing and refining the use of animal models.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"36 1","pages":"2588739"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of a twin pregnancy patient with Glanzmann thrombasthenia might be caused by a novel <i>ITGA2B</i> gene mutation (c.2822G>A): a case report and family investigation.","authors":"Xiangcheng Liao, Ruikai Zhu, Zhigang Yang, Aiqiu Qin, Yucong Huang, Ping Li, Liling Liu, Zhuning Mo","doi":"10.1080/09537104.2025.2470758","DOIUrl":"10.1080/09537104.2025.2470758","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Mutations in the ITGA2B or ITGB3 gene that encodes for the αIIbβ3 platelet integrin usually cause Glanzmann thrombasthenia (GT). This study aims to investigate the clinical characteristics of a pedigree exhibiting an inherited hemorrhagic disorder resembling GT, elucidate its molecular pathogenesis and evaluate the efficacy of blood management strategies for a proband who is pregnant with twins. The clinical data of the pedigree with inherited hemorrhagic disorder were collected, including the assessment of clinical, laboratory and thromboelastography (TEG) profiles. DNA samples were obtained for next-generation sequencing, encompassing the exons and flanking sequences of the ITGA2B and ITGB3 genes, as well as other genes associated with blood and immune deficiency. Bioinformatics software tools, such as PolyPhen-2, SIFT and MutationTaster, were employed to analyze the functional impact of mutations. Protein structural models for the new mutation type were generated using PyMOL. The phenotype of the proband in this pedigree with inherited platelet dysfunction and bleeding disorder was in accordance with GT. The proband shows persistent blood accumulation in the uterine cavity. Laboratory findings indicate normal PLT morphology, PLT count, MPV, and PDW. However, there is a decreased PLT aggregation induced by agonists ADP, collagen, and AA while maintaining a normal response to ristocetin. The initial TEG examination results indicated that the patient presented with a hypocoagulable state, characterize d by a reduction in α angle (46.9), an extended K value (4.6) and a decreased maximum amplitude (35.1). The younger sister demonstrated comparable TEG performance to that of the proband and has a documented history of abnormal bleeding. A novel heterozygous mutation of &lt;i&gt;ITGA2B&lt;/i&gt; at position c.2822 G&gt;A (p.Trp941*) was identified in the proband and her familial counterparts-father, brother and sister. MutationTaster software predicted the new mutation to be pathogenic; however, PolyPhen-2 and SIFT software did not provide correlated predictions. The p.Trp941* mutation resulted in the premature termination of translation at residue 940Trp, leading to impaired protein function. Successful management was achieved during the perioperative period by administration of human immunoglobulin, platelets and antifibrinolytic drugs, followed by recombinant factor VIIa (rFVIIa), according to the thromboelastography tracings. The laboratory findings of the proband are consistent with GT, and a novel mutation in the ITGA2B gene at position c.2822 G&gt;A (p.Trp941*) has been identified as a potential cause of GT. However, since GT is a recessive disorder and both the proband and her family members are heterozygous, it cannot be excluded that they may possess additional bleeding risk factors, including the presence of other undetected variants. This study also illustrates the significance of multidisciplinary planning, TEG analysis and judicious utilization of ","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"36 1","pages":"2470758"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}